Literature DB >> 25441436

Adverse technical events in home hemodialysis.

Karthik K Tennankore1, Celine d'Gama2, Rose Faratro2, Stella Fung2, Elizabeth Wong2, Christopher T Chan2.   

Abstract

BACKGROUND: There is a growing interest in home hemodialysis because of its clinical benefits. However, given that patients are responsible for performing a complex medical procedure at home, adverse-event reporting is important to ensure patient safety. The purpose of this study was to describe adverse technical events in a large cohort of home hemodialysis patients. STUDY
DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: All consecutive patients undergoing home hemodialysis at a large tertiary-care center from 1999 through 2011 (last follow-up, July 2012). OUTCOMES: Overall rate of adverse technical events and number/rate of severe adverse events (defined as those requiring intervention).
RESULTS: The cohort consisted of 202 patients with total follow-up of 757 patient-years. The cohort underwent a median of 5 dialysis treatments per week and 8 hours per session. 22 first adverse events and 7 recurrent events were identified. Adverse event rates were 0.049 per arteriovenous fistula access-year, 0.015 per arteriovenous graft access-year, and 0.022 per dialysis catheter access-year. Event rates per 1,000 dialysis treatments were 0.208, 0.068, and 0.087 for arteriovenous fistula, arteriovenous graft, and dialysis catheter access, respectively. Most adverse events were related to needle dislodgement (n=18) or air embolism (n=6). 8 adverse events resulted in emergency department visits and 5 required hospital admission. The rate of severe adverse events was 0.009 per patient-year of home hemodialysis and 0.038 per 1,000 dialysis treatments. Interventions included 3 blood transfusions, 2 catheter changes, 1 use of intravenous fluids, and 1 need for urgent dialysis. Attempts were made to retrain or review the technique in all patients with a first adverse event. LIMITATIONS: Events that were not severe may have been under-reported by patients.
CONCLUSIONS: Serious adverse technical events in home hemodialysis are relatively rare. Strategies to further prevent these events may include patient retraining and periodic vascular access technique audit.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adverse events; adverse technical events; air embolism; arteriovenous fistula; arteriovenous graft; dialysis catheter; home hemodialysis; needle dislodgement; patient training; quality assurance; safety; technical events

Mesh:

Year:  2014        PMID: 25441436     DOI: 10.1053/j.ajkd.2014.08.013

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

1.  Renal Association Clinical Practice Guideline on Haemodialysis.

Authors:  Damien Ashby; Natalie Borman; James Burton; Richard Corbett; Andrew Davenport; Ken Farrington; Katey Flowers; James Fotheringham; R N Andrea Fox; Gail Franklin; Claire Gardiner; R N Martin Gerrish; Sharlene Greenwood; Daljit Hothi; Abdul Khares; Pelagia Koufaki; Jeremy Levy; Elizabeth Lindley; Jamie Macdonald; Bruno Mafrici; Andrew Mooney; James Tattersall; Kay Tyerman; Enric Villar; Martin Wilkie
Journal:  BMC Nephrol       Date:  2019-10-17       Impact factor: 2.388

2.  Association of Vascular Access Type with Mortality, Hospitalization, and Transfer to In-Center Hemodialysis in Patients Undergoing Home Hemodialysis.

Authors:  Matthew B Rivara; Melissa Soohoo; Elani Streja; Miklos Z Molnar; Connie M Rhee; Alfred K Cheung; Ronit Katz; Onyebuchi A Arah; Allen R Nissenson; Jonathan Himmelfarb; Kamyar Kalantar-Zadeh; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2016-01-04       Impact factor: 8.237

Review 3.  Diagnosis, Treatment, and Prevention of Hemodialysis Emergencies.

Authors:  Manish Saha; Michael Allon
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-09       Impact factor: 8.237

4.  Frequent hemodialysis: history of the modality and assessment of outcomes.

Authors:  Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2017-04-11       Impact factor: 3.714

5.  Mathematical and Computational Modeling of Device-Induced Thrombosis.

Authors:  Keefe B Manning; Franck Nicoud; Susan M Shea
Journal:  Curr Opin Biomed Eng       Date:  2021-09-28

6.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

7.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

8.  Understanding Home Hemodialysis Patient Attrition: A Cohort Study.

Authors:  Bailey Paterson; Danielle E Fox; Chel Hee Lee; Victoria Riehl-Tonn; Elena Qirzaji; Rob Quinn; David Ward; Jennifer M MacRae
Journal:  Can J Kidney Health Dis       Date:  2021-06-13

9.  Are adverse events in newly trained home dialysis patients related to learning styles? A single-centre retrospective study from Toronto, Canada.

Authors:  Bourne Lewis Auguste; Michael Girsberger; Claire Kennedy; Thatsaphan Srithongkul; Margaret McGrath-Chong; Joanne Bargman; Christopher T Chan
Journal:  BMJ Open       Date:  2020-01-20       Impact factor: 2.692

10.  A device for surveillance of vascular access sites for bleeding: results from a clinical evaluation trial.

Authors:  Chang Yin Chionh; Desilyn Yuqing Soh; Chee How Tan; Jien-Yi Khaw; Ying Ching Wong; Shaohui Foong
Journal:  Sci Rep       Date:  2020-10-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.